Diabetes tech had a big week, and not the good kind for everyone. Tandem filed its tubeless Mobi with the FDA this quarter—putting a 7-day wear patch pump directly in Insulet’s lane for the first time. Medtronic cut its full-year EPS guidance after a $157 million one-time charge hit from MiniMed Flex’s early clearance—good news on the clinical side, expensive news on the balance sheet. And Boston Scientific’s PFA market share story got worse, not better, as Medtronic, J&J, and Abbott continued taking share in electrophysiology while BSX’s Watchman franchise stumbled. Welcome to Issue #21.
Top Stories
Story 01
Tandem Diabetes Care confirmed it filed a 510(k) submission with the FDA for its first tubeless insulin pump this quarter, targeting clearance in the second half of 2026. The device is a tubeless version of the company’s Mobi pump—the world’s smallest durable insulin pump—powered by Tandem’s newly cleared SteadiSet 7-day infusion set. If cleared, the tubeless Mobi would be the first patch pump with extended 7-day wear, more than doubling the 72-hour pod replacement cycle that Insulet’s Omnipod line currently requires. CEO John Sheridan called the tubeless option a “competitive advantage in a market growing roughly 20%” as Tandem targets patients who want the flexibility to switch between tubed and tubeless wear within the same device ecosystem. (Source: Yahoo Finance / MedTech Dive, May 2026)
The tubeless Mobi would launch through a phased rollout beginning with small patient cohorts. Tandem is also targeting 65% gross margins by 2027 and a shift toward pharmacy distribution—a channel strategy designed to reduce dependence on durable medical equipment reimbursement pathways and improve patient access. The company faces a market increasingly dominated by Insulet, whose Omnipod 5 posted 34% revenue growth in Q1 2026, but Tandem’s differentiated 7-day wear timeline and dual-mode architecture (tubed or tubeless) offers a clinical and logistical profile that no current patch pump matches.
Why It Matters: The insulin pump market competes on wear time, ease of use, and reimbursement access—in that order. A 7-day tubeless pump that users can switch on or off from a tubed configuration is a meaningful architecture differentiation. If the clinical data holds up and clearance comes, Tandem enters a growth market from a position of structural distinctiveness rather than pure price competition.
Diabetes Tech
FDA Filing
Innovation
Why This Matters for Builders
Tandem is not trying to beat Insulet on the same axis. Insulet owns the patch pump space and has compounding reimbursement infrastructure in Europe. Tandem’s tubeless Mobi competes on a different dimension entirely: the dual-mode architecture lets a patient switch between tubed and tubeless wear, which Omnipod cannot do. This is a textbook “compete on orthogonal differentiation” strategy. When the market leader has locked down one dimension (convenience + tubeless), you win by adding a dimension they structurally cannot offer without a full product rebuild. The platform advantage beats the feature advantage every time—but only if the underlying platform is actually differentiated. Tandem’s Mobi is.
Story 02
Medtronic revised its full-year fiscal 2026 adjusted EPS guidance downward to a range of $5.50–$5.54, from the previous range of $5.62–$5.66, after disclosing a one-time $157 million charge in Q4 related to MiniMed. The charge was triggered by the FDA’s clearance of MiniMed Flex—a next-generation automated insulin delivery system—several months earlier than Medtronic had modeled. MiniMed’s R&D was partially funded by affiliates of Blackstone through a 2020 agreement; the FDA clearance triggered a payment obligation to Blackstone that Medtronic was required to book immediately. MiniMed separately completed an IPO, diluting Medtronic’s ownership interest and creating a second financial impact. (Source: Drug Delivery Business / Seeking Alpha, May 2026)
MiniMed Flex received FDA clearance “several months earlier than anticipated,” according to Medtronic’s 8-K filing—a rare case where an earlier-than-expected regulatory approval created an immediate financial liability rather than a pure financial benefit. The underlying clinical story is positive: MiniMed Flex is a next-generation AID system designed to replace the MiniMed 780G and compete directly with Insulet’s Omnipod 5 and Tandem’s Control-IQ. But the earnings hit reflects the complexity of private equity-funded R&D arrangements, where regulatory milestones directly trigger cash payment obligations regardless of timing.
Why It Matters: Medtronic’s guidance cut is not a sign of business weakness—it is the accounting consequence of a deal structure built in 2020 that nobody modeled against an early FDA clearance. The lesson is structural: when you fund R&D through PE milestone agreements, you give up control of the timing of your expense recognition. The FDA’s approval calendar is not predictable enough to use as a fixed financial planning assumption.
Guidance Cut
Diabetes Tech
FDA Clearance
Know someone building or investing in MedTech?
Forward this issue. Five minutes of signal, no noise.
Industry Shift
Story 03
Boston Scientific’s guidance cut from April 22—reducing full-year 2026 sales growth to 7%–8.5% from 10.5%–11.5%—was driven in significant part by unexpected market share erosion in pulsed-field ablation (PFA), where Medtronic’s PulseSelect, Johnson & Johnson’s Varipulse, and Abbott’s Volt system have been taking share from BSX’s Farapulse, which was the category pioneer. CEO Mike Mahoney acknowledged the company lost EP share “faster than expected” in Q1 2026. Adjusted gross margin fell 100 basis points, primarily from tariff impacts and inventory charges tied to the discontinuation of the PolarX cryoablation system. The Watchman LAA occlusion franchise also declined, with procedural volumes weakening since February. (Source: MedTech Dive, April 22 / May 2026)
PFA is one of the fastest-growing segments in cardiac electrophysiology—a non-thermal ablation technique that selectively targets cardiac tissue while sparing surrounding structures. BSX’s Farapulse was the first PFA system cleared in the U.S. and built a strong early market position. But first-mover advantage in device markets has a well-documented shelf life: competitors studied Farapulse’s clinical data, designed around its limitations, and launched with comparable efficacy claims and strong commercial infrastructure. The tariff headwind compounds the problem—BSX manufactures significant device volume outside the U.S., and tariff impacts flow directly into gross margin before any volume recovery can offset them.
Why It Matters: First-mover advantage in MedTech is real but temporary. Farapulse defined the PFA category. The clinical community adopted it, published the outcomes data, and then used that same data to evaluate Medtronic’s, J&J’s, and Abbott’s entrants. This is the standard pattern: pioneer defines the market, establishes the clinical benchmark, then watches well-capitalized incumbents compete directly on the same benchmark. The only durable moat in device markets is either a structural manufacturing advantage, a locked-in platform (hospital contract + disposables ecosystem), or a next-generation clinical breakthrough. Farapulse had none of the three at scale before the competition arrived.
Electrophysiology
Guidance Cut
Tariffs
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $457.20 | ▲ 1.2% |
| SYK | Stryker | $295.10 | ▲ 0.9% |
| BDX | BD (Becton Dickinson) | $147.30 | ▲ 1.8% |
| JNJ | Johnson & Johnson | $222.40 | ▼ 1.0% |
| ABT | Abbott | $87.90 | ▲ 1.9% |
| EW | Edwards Lifesciences | $84.60 | ▲ 1.7% |
| ZBH | Zimmer Biomet | $83.10 | ▲ 0.3% |
| MDT ★ | Medtronic | $74.90 | ▼ 3.5% |
| GEHC | GE HealthCare | $62.40 | ▲ 1.1% |
| BSX | Boston Scientific | $54.80 | ▼ 2.1% |
★ Biggest Mover: MDT fell 3.5% on the week as Medtronic disclosed its FY2026 EPS guidance cut, lowering adjusted EPS projections to $5.50–$5.54 from $5.62–$5.66 following a $157 million one-time charge related to MiniMed Flex’s early FDA clearance and the associated Blackstone payment obligation. BSX extended its post-guidance-cut weakness. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of May 4–11, 2026. For illustrative purposes only.
Deep Dive
The Diabetes Tech War Is Entering Its Hardware Phase
Three companies are fighting for the insulin delivery market in 2026, and they are no longer competing on the same product architecture. This is what a maturing market looks like when the clinical baseline is proven and the competition shifts from “does it work” to “who can reach the most patients at the lowest friction.”
- Insulet owns the tubeless patch pump category—for now. Omnipod 5 posted 34% revenue growth in Q1 2026 on expanding European reimbursement. The system has been commercially available for years, is covered by major payers in the U.S. and Europe, and has a growing clinical evidence base in Type 1 and Type 2 diabetes. The commercial moat is real: pharmacy distribution, established reimbursement pathways, and brand recognition among endocrinologists and patients. Insulet’s core risk is that the next entrant competes on a dimension—like wear time—where Omnipod’s 72-hour pod cycle is structurally limited.
- Tandem is betting on architecture, not just wear time. The tubeless Mobi is not a pure patch pump—it is a convertible device that lets users switch between tubed and tubeless wear. This dual-mode architecture is clinically relevant for patients who need tubing for high-activity or sleep scenarios but want tubeless flexibility during the day. Tandem’s SteadiSet infusion set, recently cleared for 7-day wear, is the enabling technology. If the FDA clears the tubeless Mobi in H2 2026, Tandem enters the patch pump market with a wear-time and flexibility advantage that Insulet cannot quickly replicate without a full product redesign.
- Medtronic is rebuilding under pressure. MiniMed Flex’s early FDA clearance is good news for patients and for Medtronic’s long-term competitive position in AID systems. But the $157 million charge reveals the structural risk of milestone-based PE financing: when regulatory timelines compress, the expense obligations are front-loaded without the revenue to offset them. MiniMed is now public and operating independently; Medtronic’s remaining interest means it benefits from MiniMed’s upside but took the immediate financial hit of the milestone trigger.
The insulin pump market is becoming the diabetes tech version of the surgical robotics market: multiple well-capitalized entrants competing on differentiated architectures, with reimbursement access as the ultimate commercialization bottleneck. The clinical evidence exists for AID systems broadly. The battle is now for payer coverage, pharmacy distribution, and physician recommendation patterns—all slow-moving, durable advantages that take years to build and are hard to replicate with a product alone.
The Builder’s Take
Medtronic’s $157M Charge Is a Warning About PE-Funded R&D Deal Structures.
When Medtronic and Blackstone structured the MiniMed R&D deal in 2020, regulatory milestone payments were the mechanism used to align incentives: Blackstone funds the R&D risk, and gets paid when regulatory events happen. Standard structure. The problem is that FDA clearance timelines are not predictable, and structuring large cash obligations around a regulatory calendar you don’t control is a financial planning risk that doesn’t show up on a model until the clearance happens months early. Medtronic booked a $157 million charge because the FDA moved faster than the deal assumed. No one was wrong—the deal worked exactly as intended. But the lesson for anyone structuring PE-backed device R&D arrangements: milestone triggers tied to FDA actions need scenario planning that models early clearance as a risk, not just a upside. Early approvals are not always free.
⏳ That’s your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact — Insulin Pump History
The first wearable insulin pump was developed by Dean Kamen in the early 1970s—the same inventor who later created the Segway and the iBOT wheelchair. Kamen’s SEGA (Self-Contained Glucose Analyzer and Insulin Delivery System) prototype was not commercialized, but it established the technical concept of continuous subcutaneous insulin delivery. The first commercial insulin pump, the Auto-Syringe AS6C, reached patients in 1979. Omnipod’s tubeless architecture did not arrive until 2005. The 7-day wear cycle Tandem is now targeting would be the longest continuous wear period in commercial insulin pump history.
Trivia
MedTech Trivia
Pulsed-field ablation (PFA) uses electrical fields rather than heat or cold to destroy cardiac tissue in arrhythmia treatment. What is the primary clinical advantage of PFA over conventional thermal ablation methods like radiofrequency ablation (RFA) and cryoablation, and which Boston Scientific system was the first PFA device cleared by the FDA in the United States?
Your answer:
Think you know? 👇 Scroll to the footer for the answer.
👇 Answer at the bottom ↓
MedTech Word Search
🧩 MedTech Word Search — Issue #21 Edition — Click letters to highlight found words
Words are hidden in all directions — horizontal, vertical, diagonal, and reversed. Find all 10 MedTech terms.
Quick Question
Tandem’s tubeless Mobi competes on architecture: dual-mode tubed/tubeless, 7-day wear. Insulet’s Omnipod competes on reimbursement coverage, brand, and pharmacy access. Which wins the insulin pump market over the next five years—the better product or the better distribution? Hit reply. I read every response.
If you’re building, hiring, or investing in MedTech, reply and tell me what you’re seeing. I read every response.
Sponsor
